Bioceltix S.A. (BCX.WA)
Warsaw · PLN · Healthcare · Biotechnology
PLN 72.90 (+7.52%) as of
Key statistics
- Market cap
- 403.30M
- Forward P/E
- -18.23
- EPS (TTM)
- -3.47
- Dividend yield
- 0.00%
- 52-week range
- 57.50 – 102.00
- Beta
- 0.91
- Profit margin
- 0.00%
- Analyst target
- PLN 119.00
- Volume
- 33.97k
About Bioceltix S.A.
Bioceltix S.A. engages in the development of veterinary biologics based on mesenchymal stem cells. The company's products include BCX-CM-J, a stem-cell based medicinal drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, an allogeneic stem cell-based medicinal product for the treatment of atopic dermatitis in dogs; and BCX-EM, an allogeneic stem cell-based medicinal product for the treatment of osteoarthritis in horses. It also develops BCX-CM-Sec, a research project aimed at developing a cell-free biological drug to treat atopic dermatitis in dogs. The company was founded in 2016 and is headquartered in Wroclaw, Poland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Wroclaw, Poland
- Employees
- 49
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.